Korean J Neuromuscul Disord.
2024 Dec;16(2):43-46. 10.46518/kjnmd.2024.16.2.43.
Immune Checkpoint Inhibitor-associated Myositis in a Patient with Metastatic Cholangiocarcinoma
- Affiliations
-
- 1Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2563017
- DOI: http://doi.org/10.46518/kjnmd.2024.16.2.43
Abstract
- An 83-year-old man with cholangiocarcinoma developed immune checkpoint inhibitor-associated myositis after two cycles of durvalumab, presenting with muscle weakness and myalgia. His serum creatine kinase (CK) level peaked at 26,329 U/L. Needle electromyography confirmed a myogenic process, and MRI revealed extensive muscle edema. Muscle biopsy indicated multifocal necrotic fibers. Following steroid treatment, his CK levels normalized and muscle strength returned. This case represents the first reported instance of durvalumab-associated myositis in Korea.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of advanced urogenital cancers with immune checkpoint inhibitors
- Rituximab Treatment for Polyneuropathy Induced by an Immune Checkpoint Inhibitor
- Gut microbiome and checkpoint inhibitor colitis
- Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
- Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors
